Arcutis Biotherapeutics recently announced that the U.S. Food and Drug Administration (FDA) approved their new drug application for ZORYVE® (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in
The U.S. Food and Drug Administration (FDA) recently issued a notification to isotretinoin manufacturers to state that they must modify the iPledge Risk Evaluation and Mitigation Strategy (REMS). Originally implemented
Dermavant Sciences recently announced positive results from their phase 4 open-label clinical trial of VTAMA® (tapinarof) cream 1% for the treatment of plaque psoriasis in the head and neck region
Biopharmaceutical company, Almirall, recently announced in a press release that the European Commission (EC) has granted approval for EBGLYSSⓇ (lebrikizumab) for moderate-to-severe atopic dermatitis (AD) in patients 12 years and
The treatment and management of vitiligo can be challenging for both patients and their providers. Vitiligo carries a significant disease burden, both physically and mentally. Furthermore, due to the lack
A recent study published in the Journal of the American Academy of Dermatology sought to evaluate the prevalence of allergic contact dermatitis (ACD) in children with atopic dermatitis (AD). According
Hyperhidrosis (HH) is a condition characterized by excessive sweating beyond what is necessary for thermoregulation and affects millions of people worldwide. It can be a debilitating condition, often causing social
Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of moderate-to-severe hidradenitis suppurativa (HS) in adults. Cosentyx is the first interleukin-17A
Bausch Health has announced that the U.S. Food and Drug Administration (FDA) has approved IDP-126 (Cabtreoâ„¢) for the treatment of acne in patients aged 12 years and older. IDP-126 (clindamycin
The U.S. Food and Drug Administration (FDA) has approved BIMZELX® (bimekizumab-bkzx) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is
AbbVie recently announced that its phase 2b study evaluating upadacitinib (RINVOQ®) for the treatment of adults with nonsegmental vitiligo (NSV) met the primary endpoint of percent change from baseline in
Arcutis Biotherapeutics recently announced that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) for the expanded indication of ZORYVE (roflumilast) cream 0.3% for the
Kenvue recently revealed that an over-the-counter (OTC) moisturizer containing 1% colloidal oatmeal was shown to be effective in improving Eczema Area and Severity Index (EASI) scores in Black children. Colloidal
In a recent study, researchers aimed to characterize somatosensory profiles in patients with hidradenitis suppurativa (HS) at clinically affected and nonaffected areas compared with pain-free reference data. They noted that
Arcutis Biotherapeutics recently announced the interim results of its phase 3, long-term extension trial of roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children 6
Early in 2023, a group of nine dermatologists met to review and discuss the current literature on acne to understand both the socioeconomic and psychological effects of this skin condition
Researchers sought to clarify the association between age and sex with various comorbidities in patients with alopecia areata.
Karan Lal, DO, MS, is a double-board-certified dermatologist who specializes in adult, pediatric, and cosmetic dermatology. His impressive educational background serves as a demonstration of his long-time interest and dedication
Study evaluates efficacy of oral supplement containing hydrolyzed collagen and amino acids with drug treatments in patients with hair loss.
ExoCel Bio™ has announced the launch of Refine, their new Exovex™ serum with a 75 billion concentration of exosomes, designed for hair regrowth. This high concentration of non-lyophilized, purified exosomes
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
Sign up to receive updates on educational opportunities, complimentary content, exclusive discounts, and more.
